Satellos Bioscience (MSCL) AI Stock Analysis

• Market Cap: C$153.97M
• Dividend Yield: N/A
• Average Volume (3M): 178.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: N/A
• EPS Growth: 27.53%
• Country: CA
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 185,507,160
• 10 Day Avg. Volume: 239,110
• 30 Day Avg. Volume: 178,539
• PEG Ratio: -0.10
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$1.20
• Price Target Upside: 44.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.78 ▼(-6.27% Downside)

The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn with funding/dilution risk). Technicals are moderately supportive with price above major moving averages, but momentum signals are mixed. Valuation remains challenging due to negative earnings and no dividend.

Positive Factors

Low Financial Leverage

No recorded debt reduces fixed obligations and bankruptcy risk, giving management flexibility to prioritize R&D and pursue non‑dilutive funding. For a pre‑revenue biotech, low leverage materially extends strategic optionality and funding runway over coming quarters.

Focused Therapeutic Niche

A concentrated focus on muscle regeneration and Duchenne muscular dystrophy builds domain expertise and a clear clinical roadmap. The structural unmet need in rare muscle diseases supports durable scientific value and potential long‑term commercial opportunity if clinical success is achieved.

Stabilizing Recent Losses

A modest improvement in TTM net loss suggests some stabilization of spending or program prioritization. If this trend persists, it can modestly extend runway, allow more disciplined program sequencing, and reduce near‑term financing pressure over multiple reporting periods.

Negative Factors

Persistent Heavy Cash Burn

Consistent, large negative operating cash flow rapidly depletes liquidity and forces reliance on external capital. For a pre‑revenue developer, this structural burn profile increases fundraising frequency, dilution risk, and constrains sustained execution of clinical programs.

Pre‑revenue with Widening Losses

Absence of revenue leaves profitability entirely dependent on R&D outcomes and financing. Widening net losses over multiple years reduce visibility into sustainable margins and make long‑term viability contingent on clinical/regulatory success or continual external funding.

Declining Equity / Dilution Risk

A material drop in equity erodes the capital cushion and reflects accumulated losses or dilution. This contraction increases the probability of future equity raises, raising shareholder dilution risk and tightening the firm's ability to absorb further development costs over the medium term.

Satellos Bioscience Business Overview & Revenue Model

Company Description

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

How the Company Makes Money

Satellos Bioscience generates revenue primarily through research and development partnerships, grants, and potential future licensing agreements for its proprietary technologies. The company collaborates with other biopharmaceutical firms and research institutions to advance its therapeutic candidates, receiving funding and milestone payments as these projects progress. Additionally, Satellos may pursue revenue through out-licensing its platform to other companies, allowing them to develop new treatments based on Satellos technology, which could result in royalties and license fees.

Satellos Bioscience Financial Statement Overview

Summary

Satellos Bioscience has no revenue and increasing operational losses. Despite a strong equity position with zero debt, the company's sustainability hinges on continued financing due to negative cash flow and operational losses.

Income Statement

Satellos Bioscience shows no revenue generation over the analyzed periods with growing negative gross profit and net income, indicating increasing operational losses. The company’s EBIT and EBITDA margins are also negative, reflecting significant operational expenses relative to non-existent revenue.

Balance Sheet

The balance sheet reflects a strong equity position with zero debt, which is positive from a financial health perspective. However, the absence of revenue challenges the sustainability of operations. The equity ratio is high, indicating reliance on equity financing, which is typical for early-stage biotechnology firms.

Cash Flow

Operating cash flow is consistently negative, illustrating ongoing cash burn without revenue offset. While the company has successfully raised financing, resulting in positive cash flow from financing activities, the free cash flow remains negative, posing a risk if financing cannot be sustained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-5.57K	-20.00K	-8.82M	-3.73M	-119.92K	-48.16K
EBITDA	-24.90M	-28.08M	-15.71M	-8.09M	-4.60M	-1.61M
Net Income	-23.68M	-28.10M	-15.89M	-11.32M	-15.51M	-1.58M
Balance Sheet
Total Assets	37.50M	73.02M	44.30M	6.20M	12.59M	1.13M
Cash, Cash Equivalents and Short-Term Investments	34.61M	69.85M	39.59M	1.92M	4.87M	717.53K
Total Debt	0.00	0.00	0.00	0.00	0.00	1.09M
Total Liabilities	3.50M	5.16M	3.62M	2.83M	2.10M	1.31M
Stockholders Equity	34.00M	67.86M	40.67M	3.37M	10.48M	-183.84K
Cash Flow
Free Cash Flow	-24.15M	-24.98M	-14.52M	-5.79M	-5.04M	-1.66M
Operating Cash Flow	-24.14M	-24.98M	-14.50M	-5.78M	-5.03M	-1.66M
Investing Cash Flow	-18.48M	6.34M	-17.54M	-3.00K	1.74M	0.00
Financing Cash Flow	55.34M	53.48M	51.03M	2.77M	7.45M	1.98M

Satellos Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Positive. The current price of 0.83 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.70, and above the 200-day MA of 0.66, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 70.22 is Negative, neither overbought nor oversold. The STOCH value of 78.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MSCL.

Satellos Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HBP	52 Neutral	C$183.31M	-29.02	-66.34%	―	―	59.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	47 Neutral	C$153.97M	-4.53	-89.10%	―	―	27.53%
MDNA	44 Neutral	C$64.60M	-5.54	-91.21%	―	―	54.74%
ARCH	26 Underperform	C$83.96M	-34.60	―	―	―	10.49%

Satellos Bioscience Corporate Events

Satellos Bioscience to Present at December Investor Conferences

Satellos Bioscience Inc. announced its participation in two upcoming investor conferences in December, where it will present and engage in discussions on polypharmacy in DMD and neuromuscular diseases. This participation highlights Satellos’s strategic efforts to engage with investors and stakeholders, potentially impacting its industry positioning by showcasing its innovative treatments and ongoing clinical developments.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience Unveils Groundbreaking Research in Duchenne Muscular Dystrophy Treatment

Satellos Bioscience announced a significant publication in Nature Communications that supports its innovative treatment approach for Duchenne Muscular Dystrophy (DMD). The research, conducted by the Ottawa Hospital Research Institute, reveals that DMD begins as a stem cell disease during fetal development, characterized by muscle stem cell dysfunction. By targeting the AAK1 protein, Satellos’ approach aims to restore muscle regeneration, offering a potential new pathway for treating DMD. This breakthrough could redefine treatment strategies and improve outcomes for patients with DMD, highlighting the importance of addressing stem cell dysfunction in muscle diseases.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience Strengthens Leadership and Advances Clinical Trials for DMD Treatment

Satellos Bioscience announced the appointment of Mark Nawacki to its Board of Directors, leveraging his extensive experience in pharmaceuticals and corporate development to guide the company’s growth. The company has made significant strides in its clinical programs, including the submission of an IND application to the FDA for a Phase 2 trial of SAT-3247 in children with DMD, and the dosing of the first patient in a long-term study in adults. These developments are expected to enhance Satellos’ strategic positioning in the biotechnology sector and offer promising advancements for stakeholders involved in the treatment of muscular dystrophies.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience to Present at November Investor Conferences

Satellos Bioscience Inc. announced its participation in upcoming investor conferences in November, where its leadership will engage in presentations and meetings. These events provide a platform for Satellos to showcase its innovative drug development efforts, particularly SAT-3247, which is in clinical development for Duchenne muscular dystrophy (DMD). The company’s involvement in these conferences highlights its commitment to advancing its market presence and fostering stakeholder engagement.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience Advances Duchenne Treatment with New Study

Satellos Bioscience has announced the dosing of the first adult patient in its long-term follow-up study, LT-001, for SAT-3247, a novel treatment for Duchenne muscular dystrophy. The study will assess long-term safety, muscle composition, and functional outcomes, with results expected in early 2026. The company plans to expand the study to include new participants in Australia and the U.S., pending regulatory approvals. This milestone marks significant progress in developing a potential therapy that could reverse the effects of Duchenne, offering hope to patients and their families.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience Reports Positive Phase 1 Trial Results for Duchenne Muscular Dystrophy Treatment

Satellos Bioscience announced promising new data from a Phase 1a/b trial of SAT-3247, a potential treatment for Duchenne muscular dystrophy (DMD), demonstrating safety, tolerability, and significant functional improvements in adults. The trial results showed remarkable increases in grip strength and forced vital capacity, suggesting SAT-3247’s potential to transform treatment for DMD. The company is planning further studies, including a Phase 2 trial, to explore the drug’s efficacy in a broader DMD population.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.